Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics awarded inducement grants on September 1, 2026 to two new employees under its 2026 Inducement Plan, consisting of non-qualified stock options to purchase 380,575 shares at an exercise price of $23.42 per share. The package includes a 275,000-share option for Gregory Shiferman, the company's newly appointed Chief Legal Officer, with the grants made as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
Key figures
- New Hires
- 2
- Grant Date
- 2026-09-01
- Clo Grant Shares
- 275000
- Options Granted
- 380575
- Vesting Schedule
- 25% on first anniversary of start date, then 12 equal quarterly installments
- Exercise Price Usd
- 23.42
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.